Tallimustine  (Synonyms: FCE 24517)

Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent^[1][2][4].

Tallimustine (0.1-10 μM, 4 h) induces damage to purified SV40 DNA^[1].
Tallimustine (72 h ) shows cytotoxicity in CEM Cells, with an IC₅₀ of 3.5 nM^[1].
Tallimustine (25 and 100 nM, 6 days) induces erythroid differentiation of K562 cells^[2].
Tallimustine (100 nM, 6 days) increases accumulation of γ-globin mRNA in K562 cells^[2].
Tallimustine (0.5 μg/mL, 1 h) arrests SW626 cells in G2/M phase^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Tallimustine (3 mg/kg, i.p.) shows antileukaemic activity in L1210 tumor bearing mice^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

697.61

C₃₂H₃₈Cl₂N₁₀O₄

115308-98-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Herzig MC, et al. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. Biochemistry. 1999 Oct 19;38(42):14045-55.  [Content Brief]

  [2]. Bianchi N, et al. Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine. Br J Haematol. 2001 Jun;113(4):951-61.  [Content Brief]

  [3]. Erba E, et al. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. Int J Cancer. 1995 Jul 17;62(2):170-5.  [Content Brief]

  [4]. Tagliabue G, et al. Combination of the new minor groove alkylator tallimustine and melphalan. Eur J Cancer. 1997 Feb;33(2):284-7.  [Content Brief]